Texas Oncology launches 'All Behind You' campaign with LOOMIS agency, featuring patient journey stories and new branding based on research about what cancer patientsTexas Oncology launches 'All Behind You' campaign with LOOMIS agency, featuring patient journey stories and new branding based on research about what cancer patients

Texas Oncology Launches ‘All Behind You’ Campaign Based on Patient Research

2026/03/27 01:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

The Loomis Agency has launched a new advertising campaign for Texas Oncology based on commissioned research into what patients seek from a cancer care provider. The findings showed that patients want a compassionate provider they can trust that also leads in innovation, advanced treatment, and clinical expertise, which directly informed the creative direction.

Four creative concepts were developed and tested, with “All Behind You” emerging as the strongest platform for balancing Texas Oncology’s medical expertise and innovation with personal connection and empathy. The campaign follows five patients through their journeys, depicting key moments from diagnosis through interactions with their care teams, culminating as each completes treatment and returns to the lifestyle passions that matter most, supported by the care team behind them.

The work introduces a new look for Texas Oncology, including an updated logo, color palette, and messaging, and is launching across a diverse media mix that includes digital, broadcast, print, social, and other channels. Still photography for the campaign was captured by Austin-based photographer Inti St. Clair, helping bring the emotional narrative of patients and care teams to life.

This campaign matters because it represents a shift in healthcare marketing toward evidence-based messaging that addresses the dual priorities cancer patients have expressed: cutting-edge medical treatment and genuine human compassion. By grounding the campaign in actual patient research, Texas Oncology and Loomis are responding to a documented need rather than making assumptions about what resonates with those facing serious illness.

The implications extend beyond branding, as the campaign’s focus on patient journeys and care team support could influence how healthcare organizations communicate their value in a competitive landscape. The integrated media approach ensures this patient-centered message reaches broad audiences across Texas. For more information about Loomis Agency’s healthcare marketing work, visit https://theloomisagency.com/healthcare/.

In the broader context, this campaign highlights the growing importance of patient experience and trust in healthcare decision-making, particularly in oncology where treatment choices are complex and emotionally charged. By visually and narratively connecting medical innovation with compassionate support, Texas Oncology aims to position itself as a destination that understands the full spectrum of patient needs.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by Press Services. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Texas Oncology Launches ‘All Behind You’ Campaign Based on Patient Research.

The post Texas Oncology Launches ‘All Behind You’ Campaign Based on Patient Research appeared first on citybuzz.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.